BMY — Bristol-Myers Squibb Share News
0.000.00%
Last trade - 00:00- $136.49bn
- $168.55bn
- $48.19bn
U.S. STOCKS ON THE MOVE-GoPro, TXNM Energy, Emergent BioSolutions
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Oxford BioMedica slides as Novartis, Bristol-Myers Squibb pause CAR-T autoimmune trials
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Bristol-Myers Spokesperson Says Co Implemented A Voluntary Pause To Review Clinical Data Across Their Zola-Cel Program
Novartis pauses trials of experimental cell therapy after three deaths (updated)
Cytokinetics heart drug shows promise in trial, but analysts question modest benefits (updated)
Cytokinetics rises after heart disease drug shows promise in late-stage study
Cytokinetics eyes expanded use of heart drug after promising late-stage data
Bristol Myers ends blood cancer drug deal with cell therapy maker Cellares (updated)
Bristol Myers ends blood cancer drug deal with cell therapy maker Cellares
Brief: Bristol Myers Confirms That They Have Ended Partnership With Cellares, Spokesperson Says
AstraZeneca's blocked M&A signals tough CEO finale
Factbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
Brief: Chai Discovery Collaboration With Bristol Myers Squibb To Advance Ai-Driven Antibody Discovery
Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech (updated)
Brief: Mubadala Investment Co Pjsc Reports Share Stake In Ford Motor, Phillips 66, Dissolves In Apple
Brief: U.S. FDA Grants Accelerated Approval To Bristol Myers Squibb's First Celmod Therapy Zenbexus™, In Combination With Daratumumab And Hyaluronidase-Fihj And Dexamethasone (Zdd) For Patients With Multiple Myeloma, As Early As First Relapse
Brief: FDA Grants Accelerated Approval To Iberdomide With Daratumumab And Hyaluronidase-Fihj And Dexamethasone For Multiple Myeloma